← Back to headlines
Needham Maintains Buy Rating on Revolution Medicines (RVMD)
Needham has reiterated its 'Buy' rating for Revolution Medicines (RVMD), despite the company reporting a wider loss in its latest financial results.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
